Skip to content

Ophthalmic Manifestations of Patients With Mucopolysaccharidosis

Ophthalmic Manifestations of Patients With Mucopolysaccharidosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04770415
Enrollment
28
Registered
2021-02-25
Start date
2021-04-01
Completion date
2023-04-01
Last updated
2021-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ophthalmic Manifestations

Brief summary

Mucopolysaccharidosis (MPSs) are a group of disorders caused by inherited defects in lysosomal enzymes resulting in widespread intra- and extra-cellular accumulation of glycosaminoglycan(1,2). They have been subdivided according to enzyme defect and systemic manifestations and include MPS IH (Hurler)(3) , MPS IS (Scheie), MPS IH/S (Hurler/Sheie), MPS II(4,5) (Hunter), MPS III (Sanfilippo)(6) , MPS IV (Morquio)(7,8), MPS VI (Maroteaux-Lamy)(9), MPS VII (Sly)(10,11) and MPS IX (Natowicz)(12). Mucopolysaccharidosis have a spectrum of systemic manifestations, including airway and respiratory compromise, skeletal deformities, intellectual and neurological impairment, cardiac abnormalities, gastrointestinal problems and ocular manifestations(13). Ocular manifestation are common in the mucopolysaccharidosis and may result in significant visual impairment(14). Corneal opacification of varying severity is frequently seen, as well as retinopathy, optic nerve swelling and atrophy, ocular hypertension, and glaucoma(14). New treatment modalities for the systemic manifestations of the mucopolysaccharidosis include bone marrow transplant and enzyme replacement therapy have resulted in an improved prognosis in many cases(15).

Interventions

None listed

Sponsors

Shrouk Shaban Bakr
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* All patients at any age up to 18 years with any type of MPS confirmed by the enzymatic assay

Exclusion criteria

* Any patient other than MPS

Design outcomes

Primary

MeasureTime frame
early detection and management of ophthalmic manifestations in patients with MPS1 week

Countries

Egypt

Contacts

Primary ContactShrouk Shaban Bakr, Resident doctor
sshrouk617@gmail.com01069759819

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026